Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 23640103)

1.

Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.

Thompson JP, Abdolahi A, Noyes K.

Pharmacoeconomics. 2013 Jun;31(6):455-69. doi: 10.1007/s40273-013-0063-4. Review.

2.

Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.

Guo S, Pelligra C, Saint-Laurent Thibault C, Hernandez L, Kansal A.

Pharmacoeconomics. 2014 Jun;32(6):559-72. doi: 10.1007/s40273-014-0150-1. Review.

PMID:
24643323
3.

Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.

Hawton A, Shearer J, Goodwin E, Green C.

Appl Health Econ Health Policy. 2013 Aug;11(4):331-41. doi: 10.1007/s40258-013-0034-0. Review.

PMID:
23637055
4.

Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.

Asche CV, Hippler SE, Eurich DT.

Pharmacoeconomics. 2014 Jan;32(1):15-27. doi: 10.1007/s40273-013-0117-7. Review.

PMID:
24357160
5.

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. Review.

7.

Generalisability in economic evaluation studies in healthcare: a review and case studies.

Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A.

Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. Review.

8.
9.

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.

Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD, Brown M.

Value Health. 2009 Jul-Aug;12(5):657-65. doi: 10.1111/j.1524-4733.2008.00485.x. Review.

PMID:
19508662
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
11.

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K.

J Manag Care Pharm. 2007 Apr;13(3):245-61.

12.

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH; Cost Effectiveness of Multiple Sclerosis Therapies Study Group.

BMJ. 2003 Mar 8;326(7388):522; discussion 522.

13.

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.

Amato MP.

Expert Opin Pharmacother. 2004 Oct;5(10):2115-26. Review.

PMID:
15461547
14.

Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.

Owens GM, Olvey EL, Skrepnek GH, Pill MW.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S41-53. Review.

15.
16.

Review of methodological issues of clinical trials in multiple sclerosis.

Montalban X.

J Neurol Sci. 2011 Dec;311 Suppl 1:S35-42.

PMID:
22206765
17.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

18.

Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis.

Brandes DW, Raimundo K, Agashivala N, Kim E.

J Med Econ. 2013;16(4):547-51. doi: 10.3111/13696998.2013.774281. Epub 2013 Feb 21.

PMID:
23391123
19.

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW.

Neurology. 2011 Jul 26;77(4):355-63. doi: 10.1212/WNL.0b013e3182270402. Epub 2011 Jul 20.

20.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Hartung DM, Bourdette DN, Ahmed SM, Whitham RH.

Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk